Skip to main content
. Author manuscript; available in PMC: 2011 Nov 17.
Published in final edited form as: Cancer Biol Ther. 2008 Oct 3;7(10):1584–1590. doi: 10.4161/cbt.7.10.6562

Figure 2.

Figure 2

Specificity of MSLN promoter in MSLN+ and MSLN− pancreatic cancer cells based on luciferase expression. The MSLN promoter driving luciferase had a high amount of luciferase activity in the MSLN+ cancer cell line, Hs7766T, compared to the MSLN− line, PL5. To adjust for transfection efficiency between the cell lines, these data points were normalized to luciferase activity in cells transfected with CAG/Luc nanoparticles. Experiments were performed in triplicate (error bars represent SEM).